Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

被引：0
|
作者：
Moshe Talpaz
Susan Erickson-Viitanen
Kevin Hou
Solomon Hamburg
Maria R. Baer
机构：
[1] University of Michigan,
[2] Incyte Corporation,undefined
[3] Tower Hematology Oncology Medical Group,undefined
[4] University of Maryland,undefined
[5] Greenebaum Comprehensive Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Anemia; Janus kinase; Myelofibrosis; Ruxolitinib; Thrombocytopenia; Transfusion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica: A Prospective, Open-Label Study
    Hwang, Angelina S.
    Kechter, Jacob A.
    Li, Xing
    Hughes, Alysia
    Severson, Kevin J.
    Boudreaux, Blake
    Bhullar, Puneet
    Nassir, Shams
    Yousif, Miranda
    Zhang, Nan
    Butterfield, Richard J.
    Nelson, Steven
    Xing, Xianying
    Tsoi, Lam C.
    Zunich, Samantha
    Sekulic, Aleksandar
    Pittelkow, Mark
    Gudjonsson, Johann E.
    Mangold, Aaron
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (09)
  • [42] A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis
    Verstovsek, Srdan
    Hoffman, Ronald
    Mascarenhas, John
    Soria, Jean-Charles
    Bahleda, Ratislav
    McCoon, Patricia
    Tang, Weifeng
    Cortes, Jorge
    Kantarjian, Hagop
    Ribrag, Vincent
    LEUKEMIA RESEARCH, 2015, 39 (02) : 157 - 163
  • [43] Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3trial
    Harrison, Claire N.
    Mesa, Ruben
    Talpaz, Moshe
    Al-Ali, Haifa Kathrin
    Xicoy, Blanca
    Passamonti, Francesco
    Palandri, Francesca
    Benevolo, Giulia
    Vannucchi, Alessandro Maria
    Mediavilla, Clemence
    Iurlo, Alessandra
    Kim, Inho
    Rose, Shelonitda
    Brown, Patrick
    Hernandez, Christopher
    Wang, Jia
    Kiladjian, Jean-Jacques
    LANCET HAEMATOLOGY, 2024, 11 (10): : e729 - e740
  • [44] An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study
    Durrant, Simon T.
    Nagler, Arnon
    Vannucchi, Alessandro M.
    Lavie, David
    Chuah, Charles
    Passamonti, Francesco
    Gisslinger, Heinz
    le Coutre, Philipp
    Gopalakrishna, Prashanth
    Mahuzier, Bruyere
    Mo, Shuyuan
    Martinez-Lopez, Joaquin
    BLOOD, 2015, 126 (23)
  • [45] Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
    Alexander Spira
    Aaron R. Hansen
    Wael A. Harb
    Kelly K. Curtis
    Erina Koga-Yamakawa
    Makoto Origuchi
    Zhonggai Li
    Bella Ertik
    Walid L. Shaib
    Targeted Oncology, 2021, 16 : 461 - 469
  • [46] Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
    Spira, Alexander
    Hansen, Aaron R.
    Harb, Wael A.
    Curtis, Kelly K.
    Koga-Yamakawa, Erina
    Origuchi, Makoto
    Li, Zhonggai
    Ertik, Bella
    Shaib, Walid L.
    TARGETED ONCOLOGY, 2021, 16 (04) : 461 - 469
  • [47] Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
    Al-Ali, Haifa Kathrin
    Griesshammer, Martin
    le Coutre, Philipp
    Waller, Cornelius F.
    Liberati, Anna Marina
    Schafhausen, Philippe
    Tavares, Renato
    Giraldo, Pilar
    Foltz, Lynda
    Raanani, Pia
    Gupta, Vikas
    Tannir, Bayane
    Ronco, Julian Perez
    Ghosh, Jagannath
    Martino, Bruno
    Vannucchi, Alessandro M.
    HAEMATOLOGICA, 2016, 101 (09) : 1065 - 1073
  • [48] Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF)
    Bose, Prithviraj
    Pemmaraju, Naveen
    Schroeder, Kurt
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Daver, Naval
    DiNardo, Courtney D.
    Alvarado, Yesid
    Yilmaz, Musa
    Huynh-Lu, Julie
    Qiao, Wei
    Wang, Xuemei
    Matamoros, Aurelio
    Zhou, Lingsha
    Pierce, Sherry
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2017, 130
  • [49] Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
    Gowin, K.
    Kosiorek, H.
    Dueck, A.
    Mascarenhas, J.
    Hoffman, R.
    Reeder, C.
    Camoriano, J.
    Tibes, R.
    Gano, K.
    Palmer, J.
    Mesa, R.
    LEUKEMIA RESEARCH, 2017, 60 : 31 - 35
  • [50] Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis: A Phase 2 Study
    Harrison, Claire
    Garcia, Jacqueline S.
    Mesa, Ruben
    Somervaille, Tim
    Ritchie, Ellen K.
    Komrokji, Rami S.
    Pemmaraju, Naveen
    Jamieson, Catriona
    Papadantonakis, Nikolaos
    Foran, James M.
    O'Connell, Casey L.
    Verstovsek, Srdan
    Jung, Paul
    Holes, Leanne
    Masud, Abdullah
    Harb, Jason
    Hutti, Jessica E.
    Prchal, Josef T.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S325 - S325
12345